endometrial cancer (Cancer)
Information
- Disease name
- endometrial cancer
- Disease ID
- DOID:1380
- Description
- "A uterine cancer that is located_in tissues lining the uterus." [url:http\://www.cancer.gov/dictionary?CdrID=444987]
Disease area statistics
Chromosome band
Gene symbol | Chromosome | Start | Stop | The number of variant |
---|---|---|---|---|
PMS2 | 7 | 5,970,957 | 6,009,122 | 438 |
MSH6 | 2 | 47,783,145 | 47,806,953 | 430 |
FBXO11 | 2 | 47,806,920 | 47,906,498 | 380 |
MSH2 | 2 | 47,403,156 | 47,483,223 | 300 |
EPCAM | 2 | 47,369,311 | 47,387,020 | 98 |
MLH1 | 3 | 36,993,518 | 37,050,846 | 96 |
PTEN | 10 | 87,863,625 | 87,971,930 | 64 |
KCNK12 | 2 | 47,509,290 | 47,570,985 | 64 |
TP53 | 17 | 7,668,421 | 7,687,490 | 6 |
ARID1A | 1 | 26,696,015 | 26,782,104 | 6 |
Annotation
Genes | Mutation | Description | Source | Links |
---|
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT04774419 | Active, not recruiting | Phase 2 | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | April 2, 2021 | February 2025 |
NCT05796518 | Active, not recruiting | N/A | Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors | September 7, 2023 | June 2024 |
NCT00514254 | Active, not recruiting | Risk Factors for Endometrial Cancer in Black Women | July 2007 | July 2025 | |
NCT05257057 | Active, not recruiting | Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome | May 8, 2019 | December 2024 | |
NCT03603184 | Active, not recruiting | Phase 3 | Atezolizumab Trial in Endometrial Cancer - AtTEnd | October 2, 2018 | May 2025 |
NCT06293066 | Active, not recruiting | Performance of Ultrasound in Women With Postmenopausal or Abnormal Uterine Bleeding Between White and Black Ethnic Groups- a Retrospective Cohort Study. | January 31, 2024 | July 15, 2024 | |
NCT04025229 | Active, not recruiting | N/A | High Intensity Interval Training in Endometrial Cancer | May 20, 2019 | September 8, 2025 |
NCT05216913 | Active, not recruiting | Optimising Cardiovascular Health in Endometrial Cancer Survivors | February 9, 2022 | October 2024 | |
NCT04344795 | Active, not recruiting | Phase 1 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | May 6, 2020 | October 1, 2024 |
NCT04393285 | Active, not recruiting | Phase 2 | Abemaciclib and Letrozole to Treat Endometrial Cancer | October 10, 2020 | December 1, 2025 |
NCT03935256 | Active, not recruiting | Phase 2 | Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer | March 5, 2019 | December 31, 2024 |
NCT04152018 | Active, not recruiting | Phase 1 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | November 13, 2019 | August 30, 2024 |
NCT05194735 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | April 4, 2022 | November 30, 2024 |
NCT05169437 | Active, not recruiting | Phase 2 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | March 15, 2022 | January 1, 2025 |
NCT04577963 | Active, not recruiting | Phase 1/Phase 2 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | August 9, 2021 | November 2024 |
NCT05737745 | Active, not recruiting | N/A | FitEx for Endometrial Cancer Survivors: Initial Efficacy | February 1, 2023 | June 2024 |
NCT00924027 | Active, not recruiting | Phase 2 | A Study of Patients Receiving High-Dose Rate Brachytherapy | April 14, 2009 | July 5, 2025 |
NCT05717634 | Active, not recruiting | Endometrial Changes in Breast Cancer Women. | January 26, 2023 | January 26, 2024 | |
NCT05082025 | Active, not recruiting | Phase 2 | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | September 27, 2022 | October 29, 2026 |
NCT04188548 | Active, not recruiting | Phase 1 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | December 10, 2019 | December 2027 |
NCT03285230 | Active, not recruiting | The French E3N Prospective Cohort Study | June 15, 1990 | December 15, 2025 | |
NCT05035173 | Active, not recruiting | N/A | The LYSA (Linking You to Support and Advice) Trial | March 13, 2021 | April 2024 |
NCT00411138 | Active, not recruiting | Phase 3 | Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer | November 23, 2006 | December 31, 2024 |
NCT00587886 | Active, not recruiting | Estrogen, Diet, Genetics and Endometrial Cancer | September 25, 2001 | December 31, 2024 | |
NCT01068249 | Active, not recruiting | Phase 2 | Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | April 30, 2010 | April 30, 2028 |
NCT03555422 | Active, not recruiting | Phase 3 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | January 5, 2018 | December 2025 |
NCT02285192 | Active, not recruiting | Phase 1 | Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | November 2014 | November 2025 |
NCT03016338 | Active, not recruiting | Phase 2 | Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | November 6, 2017 | December 2025 |
NCT05538572 | Active, not recruiting | Phase 1 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | December 27, 2022 | December 2024 |
NCT04750941 | Active, not recruiting | Phase 2 | Study of Copanlisib and Ketogenic Diet | February 10, 2022 | December 2024 |
NCT03835819 | Active, not recruiting | Phase 2 | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) | January 2, 2020 | August 1, 2028 |
NCT03170960 | Active, not recruiting | Phase 1/Phase 2 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | September 5, 2017 | August 2024 |
NCT04660929 | Active, not recruiting | Phase 1 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | February 2, 2021 | December 31, 2024 |
NCT04000880 | Active, not recruiting | N/A | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health | March 4, 2020 | August 31, 2024 |
NCT05263492 | Active, not recruiting | Phase 2 | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer | April 1, 2022 | September 30, 2025 |
NCT03983954 | Active, not recruiting | Phase 1 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors | October 10, 2019 | October 1, 2026 |
NCT03503786 | Active, not recruiting | Phase 2 | Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer | April 1, 2018 | December 2023 |
NCT01797523 | Active, not recruiting | Phase 2 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | October 7, 2013 | October 31, 2025 |
NCT03748186 | Active, not recruiting | Phase 1 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | February 1, 2019 | November 2024 |
NCT01226316 | Active, not recruiting | Phase 1 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | December 1, 2010 | December 31, 2024 |
NCT05931445 | Active, not recruiting | N/A | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | January 26, 2021 | March 31, 2027 |
NCT01244789 | Active, not recruiting | Phase 2 | Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | December 2011 | January 15, 2025 |
NCT04780217 | Active, not recruiting | Phase 1/Phase 2 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | August 10, 2021 | August 2025 |
NCT04214964 | Active, not recruiting | Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study | April 11, 2020 | December 2024 | |
NCT03285152 | Active, not recruiting | N/A | A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients | August 11, 2017 | August 11, 2024 |
NCT00501761 | Active, not recruiting | Physical Activity After Endometrial Cancer | May 2005 | May 2025 | |
NCT03526432 | Active, not recruiting | Phase 2 | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | August 8, 2018 | May 2025 |
NCT04697264 | Active, not recruiting | N/A | Adipocytokines in Endometrial Cancer | April 12, 2021 | October 2024 |
NCT03667716 | Active, not recruiting | Phase 1 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | September 6, 2018 | May 31, 2024 |
NCT02658565 | Active, not recruiting | N/A | Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation | January 29, 2016 | November 2026 |
NCT03776630 | Active, not recruiting | N/A | Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors | May 23, 2019 | May 2027 |
NCT04681248 | Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | |||
NCT01267461 | Available | Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells | |||
NCT00268918 | Completed | Phase 1 | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | September 2005 | January 2011 |
NCT00287885 | Completed | Phase 1 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | March 2004 | December 2008 |
NCT00295945 | Completed | Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer | March 2005 | December 2009 | |
NCT00315861 | Completed | Phase 1 | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | March 2006 | January 2009 |
NCT00319748 | Completed | Phase 2 | Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | April 2006 | December 2008 |
NCT00331760 | Completed | Phase 2 | Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery | March 2006 | December 2016 |
NCT00334321 | Completed | Phase 1 | Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients | April 2006 | September 2015 |
NCT00339651 | Completed | Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer | November 25, 2002 | August 6, 2020 | |
NCT00340210 | Completed | Extended Follow-up of Columbia, MO Serum Bank Participants | January 14, 1999 | September 2, 2014 | |
NCT00340262 | Completed | Bone Mineral Density and Subsequent Cancer Risk | April 7, 2000 | March 26, 2020 | |
NCT00340600 | Completed | Continuation of Follow-up of DES-Exposed Cohorts | March 18, 1998 | November 13, 2020 | |
NCT00340808 | Completed | Molecular Staging of Endometrial Cancer | March 19, 2004 | July 16, 2020 | |
NCT00342446 | Completed | A Follow-up Study of Women Evaluated and Treated for Infertility | October 1, 1995 | January 11, 2023 | |
NCT06148129 | Completed | N/A | Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients | January 12, 2019 | March 1, 2022 |
NCT06115577 | Completed | Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes | October 1, 2012 | August 1, 2022 | |
NCT00376844 | Completed | Phase 3 | External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer | May 2002 | April 2016 |
NCT00377520 | Completed | Phase 2 | A Trial for Patients With Advanced/Recurrent Endometrial Cancer | September 2006 | September 2008 |
NCT00381888 | Completed | Phase 2 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | January 2007 | January 2009 |
NCT00388154 | Completed | Phase 2 | Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer | August 2004 | November 2013 |
NCT00392769 | Completed | Phase 2 | Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer | October 2006 | December 2010 |
NCT00401635 | Completed | Phase 2 | END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | November 2002 | |
NCT00448643 | Completed | Phase 1 | Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery | May 2002 | March 2011 |
NCT00462969 | Completed | N/A | Cytologic Analysis of Distention Media as a Screening Test for Endometrial Cancer | April 2007 | September 2010 |
NCT06049693 | Completed | Phase 4 | Iron Prehabilitation in Endometrial Cancer | January 1, 2023 | January 1, 2024 |
NCT00474994 | Completed | Phase 2 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | April 2007 | November 2010 |
NCT00482300 | Completed | N/A | Systematic Pelvic Lymphadenectomy Versus no Lymphadenectomy in Clinical Stage I-II Endometrial Cancer | ||
NCT00495235 | Completed | Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas | October 2005 | ||
NCT00505739 | Completed | Phase 2 | Mifepristone for Patients With Endometrial Cancer and LGESS | September 2001 | May 2008 |
NCT00507741 | Completed | Phase 2 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | August 2007 | April 2009 |
NCT00508703 | Completed | Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy | March 5, 2003 | September 8, 2017 | |
NCT00513786 | Completed | Phase 2 | Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | August 1, 2007 | January 3, 2017 |
NCT00515073 | Completed | Phase 2 | Papillary Serous Carcinoma of the Endometrium | April 2001 | May 2013 |
NCT00526149 | Completed | Phase 2 | BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors | July 2007 | |
NCT00542490 | Completed | Phase 2 | Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer | September 2007 | February 2016 |
NCT00543192 | Completed | Sexual Functioning in Endometrial Cancer | October 2007 | June 2009 | |
NCT00545792 | Completed | Phase 2 | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | May 2007 | October 2013 |
NCT00569257 | Completed | Phase 2 | Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors | December 2007 | July 2011 |
NCT00581646 | Completed | Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance | September 2006 | June 2015 | |
NCT00595725 | Completed | N/A | Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma | February 2003 | September 2011 |
NCT00604994 | Completed | Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer | June 2008 | April 2013 | |
NCT00607607 | Completed | Phase 2 | A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer | January 2008 | January 2012 |
NCT00610740 | Completed | Phase 2 | CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | July 2006 | April 2008 |
NCT00612495 | Completed | Phase 2 | Endometrial Cancer - LOHP Alone and With 5FU | January 2001 | March 2005 |
NCT00659568 | Completed | Phase 1 | Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma | March 2008 | August 2010 |
NCT00703807 | Completed | Phase 1 | Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers | December 2008 | May 2010 |
NCT00732173 | Completed | N/A | Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer | July 2008 | March 2011 |
NCT00735514 | Completed | Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer | July 2008 | May 2010 | |
NCT00739830 | Completed | Phase 2 | Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | August 2008 | July 2012 |
NCT00770185 | Completed | Phase 2 | Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer | November 13, 2008 | February 13, 2015 |
NCT00789893 | Completed | Study of Vaginal Dilator Use After Pelvic Radiotherapy | November 2008 | June 2015 | |
NCT00842452 | Completed | Phase 1 | Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery | February 2009 | April 2011 |
NCT00870337 | Completed | Phase 2 | Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer | March 2008 | |
NCT00879840 | Completed | Assessment of Screening Modalities for Gynecologic Cancers | April 9, 2009 | November 16, 2020 | |
NCT00002459 | Completed | Phase 3 | Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus | April 1988 | |
NCT00909896 | Completed | Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy | April 8, 2009 | January 29, 2013 | |
NCT00910091 | Completed | Phase 2 | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer | August 2009 | July 2013 |
NCT01013324 | Completed | Phase 2 | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma | January 2010 | March 2013 |
NCT01045187 | Completed | N/A | Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer | October 2008 | April 2010 |
NCT01049126 | Completed | Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients | July 2009 | February 2010 | |
NCT01065662 | Completed | Phase 1 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | February 2010 | March 2021 |
NCT01075386 | Completed | The Effects of the Endocrine System on Endometrial Cancer | October 2009 | December 2018 | |
NCT05542940 | Completed | P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer | January 1, 2020 | August 31, 2022 | |
NCT01111461 | Completed | Phase 2 | Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression | March 2010 | October 2015 |
NCT05529303 | Completed | N/A | Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients | February 26, 2023 | September 18, 2023 |
NCT05448586 | Completed | Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit? | February 2, 2019 | January 30, 2021 | |
NCT01205672 | Completed | Early Phase 1 | Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer | September 16, 2010 | May 28, 2017 |
NCT01216813 | Completed | Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer | August 2010 | December 2010 | |
NCT01237067 | Completed | Phase 1 | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | February 7, 2011 | December 12, 2019 |
NCT05378152 | Completed | N/A | Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity | September 24, 2022 | February 25, 2024 |
NCT01256268 | Completed | Phase 1 | Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids | June 13, 2011 | August 3, 2017 |
NCT01262040 | Completed | N/A | Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive | December 14, 2010 | October 29, 2018 |
NCT05364905 | Completed | Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma | May 9, 2022 | November 22, 2022 | |
NCT01364844 | Completed | Phase 1 | Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors | July 2011 | November 2013 |
NCT01367002 | Completed | Phase 2 | Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer | June 2011 | June 30, 2022 |
NCT01379534 | Completed | Phase 2 | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | November 2011 | March 2014 |
NCT01397877 | Completed | Phase 2 | GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer | December 2011 | March 2016 |
NCT01444456 | Completed | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia | October 2011 | ||
NCT05261165 | Completed | Effect of a Uterine Manipulator on the Incidence of Lymphovascular Propagation (LVSI) in Treatment of Endometrial Cancer | October 1, 2015 | October 1, 2021 | |
NCT01467219 | Completed | N/A | Pilot Study Using a PET Gamma Probe to Evaluate Lymph Nodes in Endometrial Cancer | January 2012 | March 2014 |
NCT01470677 | Completed | Phase 3 | Tachosil for the Prevention of Symptomatic Lymph Cysts | November 2011 | January 2016 |
NCT01482728 | Completed | Early Phase 1 | Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer | January 2012 | December 2015 |
NCT01512810 | Completed | Phase 2 | Intraoperative Pathological Evaluation for Surgical Treatment & Staging for Endometrial Cancer | January 2012 | August 26, 2021 |
NCT01523678 | Completed | Phase 2 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | February 2012 | August 14, 2018 |
NCT01526655 | Completed | N/A | Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer | January 25, 2012 | July 27, 2016 |
NCT01527396 | Completed | Prospective, Observational Study of Low-risk Criteria for Node Metastasis in Endometrial Cancer | December 2011 | August 2015 | |
NCT01562106 | Completed | N/A | Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery | February 2012 | August 2016 |
NCT01580696 | Completed | Phase 1/Phase 2 | Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer | April 2012 | July 31, 2016 |
NCT01582906 | Completed | A Survivorship Care Plan for Gynaecological Cancer Patients | August 2011 | April 2015 | |
NCT01588522 | Completed | Phase 1 | Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease | July 2012 | March 2017 |
NCT01610375 | Completed | N/A | Telephone Follow-up After Treatment for Endometrial Cancer | June 2012 | December 2018 |
NCT01631552 | Completed | Phase 1/Phase 2 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | December 17, 2012 | August 13, 2020 |
NCT01672892 | Completed | Phase 3 | Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer | November 2012 | May 20, 2022 |
NCT01673022 | Completed | N/A | Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging | May 2012 | January 2017 |
NCT01679483 | Completed | N/A | Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer | September 2012 | November 2015 |
NCT01679522 | Completed | N/A | Feasibility Study of Laparoendoscopic Single Site Surgical Staging for Endometrial Cancer | January 2013 | June 2022 |
NCT01686256 | Completed | Phase 1 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer | August 2001 | |
NCT01691144 | Completed | Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project | September 2012 | December 2015 | |
NCT04972682 | Completed | N/A | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer | July 1, 2021 | April 15, 2024 |
NCT01738152 | Completed | N/A | Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health | November 2012 | July 21, 2021 |
NCT04823065 | Completed | Phase 1/Phase 2 | 4FMFES-PET Imaging of Endometrial and Ovarian Cancers | September 1, 2018 | April 30, 2024 |
NCT01761721 | Completed | Robot-assisted Laparoscopic Hysterectomy-RALH- Postoperative Complications, Quality of Life and Health Economics | January 2013 | February 2016 | |
NCT01767155 | Completed | Phase 3 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer | April 2013 | January 30, 2017 |
NCT04817501 | Completed | Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System | February 14, 2014 | December 1, 2022 | |
NCT01793545 | Completed | Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples | February 11, 2013 | November 16, 2020 | |
NCT01806350 | Completed | N/A | Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors | November 2009 | September 2012 |
NCT01818739 | Completed | N/A | Lymph Node Mapping in Patients With Endometrial Cancer | March 2013 | March 31, 2017 |
NCT01836484 | Completed | Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma | June 2012 | December 2018 | |
NCT01851928 | Completed | Validation of a Nutrition Screening Tool | July 2011 | March 2013 | |
NCT01886040 | Completed | Factors Affecting the Prognosis of Patients With Endometrial Cancer | June 2013 | May 2016 | |
NCT01886066 | Completed | N/A | Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer | March 2012 | September 2021 |
NCT01911247 | Completed | Early Phase 1 | Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer | May 2011 | February 2013 |
NCT01914276 | Completed | Lymphedema in Endometrial Cancer | October 2013 | ||
NCT01922778 | Completed | N/A | Screening for Endometrial Abnormalities in Overweight and Obese Women | September 2013 | March 31, 2016 |
NCT01961102 | Completed | OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer | May 2013 | March 2016 | |
NCT01965080 | Completed | Phase 2 | Exemestane in Advanced and Recurrent Endometrial Carcinoma | March 2004 | February 2009 |
NCT01979003 | Completed | Early Phase 1 | Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion | September 2014 | June 30, 2021 |
NCT00002493 | Completed | Phase 3 | Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer | May 1992 | |
NCT02035787 | Completed | Phase 2 | Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients | February 27, 2014 | April 12, 2024 |
NCT03900104 | Completed | N/A | Cervical and Endometrial Injection for Sentinel Lymph Node Detection in Endometrial Cancer | May 1, 2019 | January 15, 2020 |
NCT03629756 | Completed | Phase 1 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | July 24, 2018 | September 3, 2021 |
NCT03665285 | Completed | Phase 1/Phase 2 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | October 1, 2018 | April 11, 2023 |
NCT06394258 | Completed | N/A | POSE - POs Surgery Endometrial Cancer | June 18, 2018 | October 8, 2021 |
NCT03694262 | Completed | Phase 2 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | July 19, 2019 | April 5, 2023 |
NCT03824613 | Completed | Urinary miRNA in Endometrial Cancer Study | March 8, 2019 | March 26, 2020 | |
NCT03722030 | Completed | N/A | Telehealth-Based Resistance Training Intervention for Endometrial Cancer Survivors | December 5, 2018 | March 14, 2020 |
NCT03820024 | Completed | N/A | MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback | September 28, 2018 | December 23, 2020 |
NCT00003669 | Completed | Phase 2 | Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer | November 1998 | April 2001 |
NCT03752606 | Completed | Phase 4 | Application of Tachosil During Lymphadenectomy | November 29, 2013 | December 31, 2017 |
NCT00003691 | Completed | Phase 3 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | December 1998 | |
NCT03813719 | Completed | Anxiety and Distress Levels in Women With Suspected Endometrial Cancer | July 1, 2018 | August 1, 2019 | |
NCT00003749 | Completed | Phase 3 | Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer | April 1998 | December 2008 |
NCT00003795 | Completed | Quality of Life in Survivors of Gynecologic Cancer | April 1999 | ||
NCT00003939 | Completed | Phase 2 | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | ||
NCT00003946 | Completed | Phase 2 | Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer | August 1999 | |
NCT00004082 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors | July 1999 | December 2010 |
NCT00004251 | Completed | Phase 2 | Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer | January 19, 2000 | January 18, 2011 |
NCT00004915 | Completed | Phase 2 | Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer | November 1998 | February 2000 |
NCT00005031 | Completed | Phase 2 | Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer | August 2000 | |
NCT00005583 | Completed | Phase 3 | Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer | January 2000 | July 2010 |
NCT00005643 | Completed | Phase 2 | Chemotherapy in Treating Patients With Sarcoma of the Uterus | May 2000 | |
NCT00005861 | Completed | Phase 2 | Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer | May 2000 | |
NCT00006005 | Completed | Phase 2 | Thalidomide in Treating Patients With Gynecologic Sarcomas | September 2000 | August 2006 |
NCT00006027 | Completed | Phase 3 | Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer | August 2000 | |
NCT00006357 | Completed | Phase 1/Phase 2 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | August 2000 | |
NCT00006377 | Completed | Phase 2 | Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer | June 2000 | January 2003 |
NCT00010829 | Completed | Phase 2 | Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors | January 2001 | December 2005 |
NCT00019331 | Completed | Phase 2 | Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors | October 1997 | May 2007 |
NCT00022620 | Completed | Phase 2 | Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer | June 2001 | |
NCT00023894 | Completed | Phase 2 | Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer | July 2001 | February 2006 |
NCT00030485 | Completed | Phase 2 | Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer | January 2002 | April 2007 |
NCT00032162 | Completed | Phase 1/Phase 2 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | August 2001 | |
NCT00033358 | Completed | Phase 2 | Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer | February 2002 | |
NCT00033605 | Completed | Phase 3 | Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis | April 2002 | July 2006 |
NCT00052312 | Completed | Phase 2 | Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer | September 2002 | |
NCT00053794 | Completed | Phase 2 | Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma | June 9, 2003 | September 22, 2008 |
NCT00071929 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer | November 1999 | September 2007 |
NCT00085332 | Completed | Phase 2 | Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer) | July 2004 | |
NCT00087100 | Completed | Phase 2 | Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer | May 2006 | |
NCT00087685 | Completed | Phase 2 | RAD001 in Recurrent Endometrial Cancer Patients | June 2004 | January 2015 |
NCT00096408 | Completed | Phase 3 | Laparoscopic Approach to Cancer of the Endometrium | October 2005 | December 2018 |
NCT00099008 | Completed | Phase 1 | Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women | March 2004 | July 2006 |
NCT00122343 | Completed | Phase 2 | AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | August 2005 | January 2008 |
NCT00171808 | Completed | Phase 2 | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer | April 2005 | |
NCT00190697 | Completed | Phase 4 | A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment | January 2001 | April 2007 |
NCT00205023 | Completed | N/A | Disseminated Endometrial Cancer Cells During Sonohysterography | January 2004 | August 2006 |
NCT00245050 | Completed | Phase 3 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | April 2004 | September 2011 |
NCT00247923 | Completed | N/A | Endometrial Polyps: Pathophysiology and Clinical Consequences | October 2005 | February 2009 |
NCT00249990 | Completed | Phase 2 | Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) | April 2003 | September 2007 |
NCT00258362 | Completed | Phase 2 | Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer | July 2005 | December 2009 |
NCT00262938 | Completed | N/A | Lifestyle Change and Quality of Life in Obese Patients With Stage I/II Endometrial Cancer in Remission | February 2005 | August 2011 |
NCT00267488 | Completed | Phase 2 | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer | October 2005 | December 2007 |
NCT03169023 | Completed | N/A | Scale Down for Endometrial Cancer | February 21, 2017 | February 3, 2019 |
NCT03171506 | Completed | N/A | Targeted Disruption to Cancer Metabolism and Growth Through Dietary Macronutrient Modification | November 9, 2015 | July 18, 2017 |
NCT03189446 | Completed | Phase 2 | Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer | October 2, 2017 | October 6, 2021 |
NCT03192059 | Completed | Phase 2 | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer | July 1, 2017 | June 30, 2021 |
NCT03207074 | Completed | N/A | Can the iKnife Distinguish Between Normal and Malignant Endometrial Tissue? | June 13, 2017 | June 1, 2020 |
NCT04120649 | Completed | Different Risk Stratification Models for Prediction of Lymph Node Involvement in Endometrial Carcinoma | May 18, 2020 | August 1, 2022 | |
NCT03210129 | Completed | N/A | Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients | July 6, 2017 | February 28, 2019 |
NCT03314935 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | November 21, 2017 | November 28, 2022 |
NCT04068675 | Completed | N/A | Effects of Centering Pre-operative Counseling on Patient Reported Anxiety | February 24, 2020 | June 30, 2021 |
NCT03330015 | Completed | Patient's Experience and Choice Between Investigations for Endometrial Cancer in Postmenopausal Bleeding | June 3, 2016 | September 26, 2017 | |
NCT03339843 | Completed | Phase 2 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib | December 19, 2018 | December 20, 2023 |
NCT03345485 | Completed | Phase 1/Phase 2 | Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors | October 6, 2017 | March 29, 2023 |
NCT04021459 | Completed | N/A | Research of Circulating Tumor Cells Released During Endometrial Cancer Surgery. | September 16, 2019 | September 16, 2021 |
NCT00003127 | Completed | Phase 2 | S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer | February 1998 | July 2004 |
NCT03366480 | Completed | Phase 1/Phase 2 | A Study to Assess the Efficacy and Safety of ABTL0812 | December 1, 2016 | November 15, 2020 |
NCT03394027 | Completed | Phase 2 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | January 17, 2018 | October 7, 2021 |
NCT03395080 | Completed | Phase 2 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | March 5, 2018 | January 27, 2021 |
NCT03454451 | Completed | Phase 1 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | April 25, 2018 | February 19, 2023 |
NCT03456791 | Completed | Human Epididymis Protein 4 in Endometrial Carcinoma | December 1, 2017 | July 30, 2018 | |
NCT03466788 | Completed | N/A | Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer | March 29, 2018 | March 28, 2019 |
NCT03476798 | Completed | Phase 2 | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium | June 29, 2018 | September 29, 2023 |
NCT03962140 | Completed | CT Assessment of BMI in Endometrial Cancer Patients | August 1, 2019 | March 31, 2021 | |
NCT03514121 | Completed | Early Phase 1 | FPA150 in Patients With Advanced Solid Tumors | March 27, 2018 | May 10, 2021 |
NCT00003267 | Completed | Phase 3 | Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer | February 1998 | |
NCT00003334 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | March 1997 | |
NCT03926936 | Completed | Phase 2 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study | March 13, 2019 | December 27, 2022 |
NCT03908996 | Completed | N/A | the Effectiveness of a Weight Management Program in Patients Who Have Completed Treatment for Endometrial Cancer | February 11, 2019 | January 11, 2021 |
NCT03898947 | Completed | Endometrial Changes in Breast Cancer Women With or Without Hormonal Therapies | January 2007 | December 2019 | |
NCT02058550 | Completed | Phase 1 | Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy | September 2014 | October 23, 2020 |
NCT02068820 | Completed | N/A | Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG | September 2012 | January 2015 |
NCT02069158 | Completed | Phase 1 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor | April 2014 | May 2019 |
NCT02091050 | Completed | Phase 2 | 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy | June 2014 | January 2017 |
NCT02096783 | Completed | N/A | Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer | September 2014 | June 2016 |
NCT04705649 | Completed | N/A | Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer | July 14, 2020 | June 22, 2023 |
NCT02131558 | Completed | N/A | Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer | May 2014 | March 8, 2017 |
NCT02135562 | Completed | N/A | Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors | August 8, 2014 | April 19, 2017 |
NCT02178722 | Completed | Phase 1/Phase 2 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | July 17, 2014 | November 6, 2020 |
NCT02209532 | Completed | N/A | A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping | December 2015 | June 2017 |
NCT02226302 | Completed | Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer | July 2014 | August 2021 | |
NCT02262455 | Completed | Phase 1 | Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors | October 2014 | January 13, 2017 |
NCT02269293 | Completed | Phase 1 | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | October 13, 2014 | April 20, 2021 |
NCT00002641 | Completed | Phase 3 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | February 1995 | June 2012 |
NCT02320565 | Completed | N/A | 2D Versus 3D Radical Laparoscopic Hysterectomy for Endometrial Cancer: a Prospective Randomized Trial | October 2014 | March 2015 |
NCT02335775 | Completed | Lymph Node Counts in Endometrial Cancer Staging | July 2008 | September 2015 | |
NCT02351479 | Completed | N/A | Hula, a Physical Activity Intervention for Female-Cancer Survivors | September 2013 | December 2017 |
NCT04626895 | Completed | N/A | Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers | June 4, 2019 | October 1, 2020 |
NCT02413606 | Completed | N/A | ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? | September 2015 | March 2022 |
NCT02431676 | Completed | Phase 2 | Survivorship Promotion In Reducing IGF-1 Trial | May 2015 | December 2018 |
NCT04560491 | Completed | Intraoperative Examination of Sentinel Node in Endometrial Cancer (TRSGO-SLN-003) | February 1, 2016 | June 30, 2020 | |
NCT02466061 | Completed | N/A | TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors | July 2014 | June 2016 |
NCT04534309 | Completed | N/A | Behavioral Weight Loss Program for Cancer Survivors in Maryland | September 22, 2020 | June 30, 2023 |
NCT00002764 | Completed | Phase 3 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | April 1996 | |
NCT02549209 | Completed | Phase 2 | Pembro/Carbo/Taxol in Endometrial Cancer | August 22, 2017 | February 10, 2022 |
NCT02549989 | Completed | Phase 2 | Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | September 2015 | March 23, 2022 |
NCT04513665 | Completed | Phase 2 | ZW25 in Women With Endometrial Cancers | August 12, 2020 | March 8, 2024 |
NCT04456972 | Completed | N/A | Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers. | June 19, 2020 | January 8, 2022 |
NCT04334239 | Completed | Effectiveness of Care in Certified Cancer Centres in Germany | May 1, 2017 | August 31, 2021 | |
NCT02622776 | Completed | N/A | Advanced Methods for Cancer Detection by Vaginal Screening | February 2016 | December 2018 |
NCT00002807 | Completed | N/A | Radiation or Observation Only in Endometrial Cancer Who Have Undergone Surgery | July 4, 1996 | December 21, 2009 |
NCT02630823 | Completed | Phase 1 | MK-3475 Immunotherapy in Endometrial Carcinoma | February 5, 2016 | October 3, 2020 |
NCT00002920 | Completed | Phase 3 | S9630, Medroxyprogesterone in Treating Women With Breast Cancer | March 1997 | December 2009 |
NCT04318340 | Completed | N/A | A Novel Tapered Applicator for Vaginal Vault Brachytherapy | July 16, 2020 | March 20, 2023 |
NCT02646748 | Completed | Phase 1 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | January 25, 2016 | November 20, 2020 |
NCT04302714 | Completed | N/A | Hysteroscopic vs. Cervical Injection for Sentinel Node Detection of Endometrial Cancer | March 20, 2017 | February 25, 2020 |
NCT04298827 | Completed | N/A | Gyn Onc Prehab Study | July 21, 2020 | March 1, 2024 |
NCT04281043 | Completed | Quality of Life After Robotic Surgery for Endometrial Cancer | June 15, 2019 | September 15, 2021 | |
NCT02690766 | Completed | N/A | Translating Healthy Lifestyle Interventions for Cancer Survivors | March 2015 | May 2016 |
NCT02714621 | Completed | N/A | MR-HIFU for Recurrent Gynaecological Cancer | May 2016 | March 31, 2020 |
NCT02725489 | Completed | Phase 2 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | June 3, 2016 | December 2, 2020 |
NCT02730416 | Completed | Phase 2 | Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer | December 12, 2016 | November 25, 2021 |
NCT02730429 | Completed | Phase 2 | Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer | February 15, 2017 | December 15, 2021 |
NCT02744898 | Completed | Phase 2 | A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus | July 2016 | March 1, 2020 |
NCT04246580 | Completed | Evaluation of Indocyanine Green-guided Systematic Pelvic Lymphadenectomy in Endometrial and Cervical Cancer | January 2014 | November 2022 | |
NCT04240730 | Completed | Transvaginal Natural Orifice Endoscopic Surgery for Extremely Obese Patients With Early-stage Endometrial Cancer | January 1, 2019 | June 30, 2019 | |
NCT02767362 | Completed | Early Phase 1 | A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium | November 2015 | September 26, 2019 |
NCT02774395 | Completed | Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine | May 2016 | May 2018 | |
NCT02826291 | Completed | SLNM in Endometrial Cancer Combined With OSNA | March 2016 | February 1, 2018 | |
NCT02834988 | Completed | Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer | July 28, 2016 | February 10, 2020 | |
NCT04237090 | Completed | Phase 3 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel | February 14, 2020 | September 4, 2020 |
NCT02912767 | Completed | Prevalence of Self Reported Lymphedema in Patients With Endometrial Cancer | July 20, 2016 | June 1, 2020 | |
NCT02914470 | Completed | Phase 1 | Carboplatin-cyclophosphamide Combined With Atezolizumab | January 2017 | October 2021 |
NCT00002949 | Completed | Phase 1 | Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis | July 1996 | May 2001 |
NCT02943811 | Completed | Effect of Uterine Manipulator on Recurrence and Mortality of Endometrial Cancer | October 2016 | October 2016 | |
NCT02987777 | Completed | Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer | January 2016 | August 2016 | |
NCT02988817 | Completed | Phase 1/Phase 2 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | November 23, 2016 | November 12, 2021 |
NCT03015129 | Completed | Phase 2 | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | January 2017 | December 30, 2022 |
NCT04212377 | Completed | Phase 2 | Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients | April 8, 2019 | March 9, 2021 |
NCT04205630 | Completed | Phase 2 | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | May 28, 2020 | April 25, 2023 |
NCT04956601 | Not yet recruiting | N/A | Adjuvant Radiotherapy in Patients With Early Endometrial Cancer | July 2021 | August 2029 |
NCT05974995 | Not yet recruiting | N/A | Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer | September 1, 2023 | September 1, 2029 |
NCT06366347 | Not yet recruiting | Phase 2 | ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | September 2024 | March 1, 2029 |
NCT06360653 | Not yet recruiting | N/A | a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer | June 2024 | June 2026 |
NCT05998798 | Not yet recruiting | Revealing Engagement Patterns Among Endometrial Cancer Patients | September 2024 | September 2026 | |
NCT06284343 | Not yet recruiting | Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study | April 1, 2024 | September 30, 2026 | |
NCT06066216 | Not yet recruiting | Phase 2 | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | February 1, 2024 | October 31, 2026 |
NCT05289648 | Not yet recruiting | Early Phase 1 | Niraparib in High-grade Endometrial Cancer Trial | May 1, 2024 | January 31, 2026 |
NCT05783986 | Not yet recruiting | Developing a MRI-based Deep Learning Model to Predict MMR Status | April 17, 2023 | December 31, 2024 | |
NCT05793333 | Not yet recruiting | Predictors of Node Positivity in Endometrial Cancer | August 10, 2023 | December 31, 2023 | |
NCT05489848 | Not yet recruiting | Phase 2/Phase 3 | Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation | August 20, 2022 | August 20, 2030 |
NCT06440018 | Not yet recruiting | INSPIRE: A Multi-Cancer Early Detection Study | June 20, 2024 | February 28, 2025 | |
NCT05524389 | Not yet recruiting | Phase 3 | Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions | December 1, 2022 | June 30, 2027 |
NCT06385548 | Not yet recruiting | Phase 1/Phase 2 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer | May 2024 | April 2026 |
NCT06463028 | Not yet recruiting | Phase 2 | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer | September 30, 2024 | September 2029 |
NCT06073184 | Not yet recruiting | Phase 2 | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium | September 2024 | September 2031 |
NCT06297811 | Not yet recruiting | Phase 2 | Myeloprotection With Trilaciclib in Pan-cancer Population | March 1, 2024 | December 31, 2027 |
NCT05550558 | Not yet recruiting | Phase 2 | Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer | November 1, 2022 | November 30, 2027 |
NCT06409052 | Not yet recruiting | Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women | August 30, 2024 | August 3, 2026 | |
NCT06340568 | Not yet recruiting | Phase 3 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer | August 2024 | December 2028 |
NCT05805358 | Not yet recruiting | Phase 2 | Hyperpolarized 13C MRI for Cancer Immunotherapy | November 1, 2023 | July 31, 2026 |
NCT06457997 | Not yet recruiting | Phase 1 | A Study of PHN-010 in Patients With Advanced Solid Tumors | July 2024 | July 2027 |
NCT03238053 | Not yet recruiting | N/A | Laser Treatment of Genito-urinary Syndrome in Women | October 1, 2022 | December 31, 2026 |
NCT05755893 | Not yet recruiting | Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53 | April 1, 2023 | August 1, 2025 | |
NCT06238284 | Not yet recruiting | HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China | January 26, 2024 | May 31, 2024 | |
NCT04227249 | Not yet recruiting | 3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer | April 2020 | March 2027 | |
NCT05824481 | Not yet recruiting | Phase 2 | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer | June 1, 2023 | June 30, 2026 |
NCT06268626 | Not yet recruiting | Detection of Endometrial Cancer Through Risk Modelling | April 2024 | January 2027 | |
NCT05795244 | Recruiting | Phase 2 | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | October 31, 2023 | December 2029 |
NCT00005095 | Recruiting | Specimen and Data Study for Ovarian Cancer Early Detection and Prevention | March 2000 | December 2040 | |
NCT02012699 | Recruiting | Integrated Cancer Repository for Cancer Research | November 1, 2013 | December 2099 | |
NCT02288676 | Recruiting | DOvEEgene: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics | January 2014 | October 2026 | |
NCT02543710 | Recruiting | Phase 4 | Biomarker Guided Treatment in Gynaecological Cancer | October 2015 | December 2033 |
NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
NCT02632448 | Recruiting | Phase 1/Phase 2 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | May 16, 2016 | September 30, 2025 |
NCT02922764 | Recruiting | Phase 1 | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | November 2016 | May 2024 |
NCT03212404 | Recruiting | Phase 1 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | September 20, 2017 | December 2024 |
NCT03366051 | Recruiting | N/A | Sentinel Node Mapping in High Risk Endometrial Cancer | December 22, 2017 | December 20, 2024 |
NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
NCT03463252 | Recruiting | Phase 2/Phase 3 | Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC | April 1, 2018 | December 30, 2030 |
NCT03538665 | Recruiting | The DETECT Study: Discovery and Evaluation of Testing for Endometrial Cancer in Tampons | July 1, 2019 | August 11, 2025 | |
NCT03543215 | Recruiting | Can Staging Magnetic Resonance Imaging (MRI) Features Prognosticate Patients Presenting With Endometrial Cancer? | July 13, 2017 | December 10, 2025 | |
NCT03675893 | Recruiting | Phase 2 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer | December 24, 2018 | August 1, 2029 |
NCT03682289 | Recruiting | Phase 2 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | January 17, 2019 | July 31, 2025 |
NCT03746431 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | January 17, 2019 | June 2026 |
NCT03785288 | Recruiting | Phase 3 | Vaginal Cuff Brachytherapy Fractionation Study | January 17, 2019 | January 1, 2026 |
NCT03787056 | Recruiting | N/A | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients | December 4, 2018 | January 4, 2028 |
NCT04463771 | Recruiting | Phase 2 | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | January 26, 2021 | May 31, 2026 |
NCT04486352 | Recruiting | Phase 1/Phase 2 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | October 20, 2021 | October 2026 |
NCT04492995 | Recruiting | Phase 2 | Sentinel Node in Endometrial Cancer | October 5, 2020 | September 30, 2023 |
NCT04504006 | Recruiting | European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III | October 10, 2017 | January 1, 2030 | |
NCT04512144 | Recruiting | N/A | Mindfulness in Endometrial and Cervical Cancer | July 25, 2020 | July 30, 2024 |
NCT04514692 | Recruiting | Phase 1/Phase 2 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging | February 1, 2021 | May 1, 2026 |
NCT04527900 | Recruiting | Phase 2 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | February 23, 2021 | September 1, 2028 |
NCT04569773 | Recruiting | Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer | September 23, 2020 | September 23, 2024 | |
NCT04570553 | Recruiting | N/A | Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers | October 15, 2020 | June 30, 2024 |
NCT04577950 | Recruiting | N/A | A Prospective Study Comparing Three Injection Sites to Detect Sentinel Lymph Nodes in Endometrial Cancer | January 21, 2021 | December 2024 |
NCT04585750 | Recruiting | Phase 1/Phase 2 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | October 29, 2020 | July 14, 2026 |
NCT04586959 | Recruiting | N/A | Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer | May 21, 2021 | October 2025 |
NCT04590326 | Recruiting | Phase 1/Phase 2 | A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 | December 9, 2020 | April 27, 2027 |
NCT04631731 | Recruiting | Phase 1/Phase 2 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity | December 15, 2020 | December 10, 2025 |
NCT04644068 | Recruiting | Phase 1/Phase 2 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | November 12, 2020 | December 15, 2026 |
NCT04683653 | Recruiting | N/A | Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | January 15, 2021 | May 22, 2025 |
NCT04706962 | Recruiting | Phase 1 | TH1902 in Patients With Advanced Solid Tumors | March 4, 2021 | December 2024 |
NCT04763915 | Recruiting | N/A | Improving Care After Inherited Cancer Testing | August 5, 2022 | December 2028 |
NCT04783467 | Recruiting | N/A | Time Restricted Eating (TRE) Among Endometrial Cancer Patients | October 7, 2021 | June 2024 |
NCT04789694 | Recruiting | Phase 3 | Prehabilitation in Gynaecological Cancer Patients | January 25, 2021 | June 30, 2026 |
NCT04845425 | Recruiting | Analysis of miRNA Expression in Endometrial Cancer | April 1, 2021 | December 2022 | |
NCT04845828 | Recruiting | N/A | Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial Cancer | January 26, 2022 | December 1, 2029 |
NCT04925284 | Recruiting | Phase 1 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | June 7, 2021 | October 7, 2024 |
NCT04930159 | Recruiting | N/A | Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence | September 1, 2021 | September 30, 2025 |
NCT04945187 | Recruiting | N/A | Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study) | May 17, 2021 | February 1, 2024 |
NCT04995731 | Recruiting | Risk Assessment of Endometrial Hyperplasia and Endometrial Cancer | September 1, 2021 | July 2024 | |
NCT04997096 | Recruiting | N/A | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy | April 2, 2022 | April 30, 2025 |
NCT05001282 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | September 13, 2021 | June 15, 2025 |
NCT05026073 | Recruiting | Vibrational Spectroscopy for Endometrial Cancer Diagnosis | January 19, 2020 | November 2024 | |
NCT05032040 | Recruiting | Phase 2 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | July 21, 2022 | May 30, 2025 |
NCT05034991 | Recruiting | The Role of Endometrial Blood Flow in Endometrial Cancer | January 5, 2021 | December 31, 2029 | |
NCT05051722 | Recruiting | Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | August 3, 2021 | December 30, 2025 | |
NCT05056077 | Recruiting | N/A | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) | October 21, 2021 | December 31, 2027 |
NCT05057013 | Recruiting | Phase 1/Phase 2 | HMBD-001 in Advanced HER3 Positive Solid Tumours | November 10, 2021 | September 2026 |
NCT05099978 | Recruiting | Asian Multicenter Prospective Study of ctDNA Sequencing | November 1, 2021 | December 31, 2024 | |
NCT05103683 | Recruiting | Phase 1 | First in Human Study of TORL-1-23 in Participants With Advanced Cancer | November 17, 2021 | November 15, 2025 |
NCT05123482 | Recruiting | Phase 1/Phase 2 | A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies | October 18, 2021 | December 30, 2025 |
NCT05129969 | Recruiting | Registry Platform Ovarian and Endometrial Cancer | November 25, 2021 | December 2027 | |
NCT05142033 | Recruiting | Avera Cancer Sequencing and Analytics Protocol (ASAP) | November 1, 2021 | December 31, 2026 | |
NCT05143970 | Recruiting | Phase 1 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | January 21, 2022 | February 2026 |
NCT05162846 | Recruiting | N/A | Methods for Increasing Genetic Testing Uptake in Michigan | April 21, 2022 | December 31, 2026 |
NCT05201547 | Recruiting | Phase 3 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | April 15, 2022 | October 2029 |
NCT05220033 | Recruiting | N/A | Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer | July 14, 2020 | December 1, 2025 |
NCT05242276 | Recruiting | Uterine Manipulator in Endometrial Cancer Surgery: Pro MUCEI Study | March 20, 2022 | March 20, 2026 | |
NCT05252416 | Recruiting | Phase 1/Phase 2 | (VELA) Study of BLU-222 in Advanced Solid Tumors | April 7, 2022 | September 30, 2026 |
NCT05255653 | Recruiting | Phase 2/Phase 3 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features | November 11, 2021 | January 1, 2031 |
NCT05287048 | Recruiting | Evaluation of MCM5 in Postmenopausal Bleeding Patients | March 1, 2022 | September 2023 | |
NCT05320757 | Recruiting | Early Phase 1 | Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients | April 1, 2022 | March 31, 2025 |
NCT05366881 | Recruiting | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | May 3, 2022 | December 2026 | |
NCT05377996 | Recruiting | Phase 1 | A Study of XMT-1660 in Participants With Solid Tumors | August 15, 2022 | May 2027 |
NCT05383482 | Recruiting | Phase 1/Phase 2 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | June 30, 2022 | December 31, 2025 |
NCT05396794 | Recruiting | Bariatric Education for Women With Obesity and Endometrial Cancer | August 30, 2023 | August 2025 | |
NCT05446324 | Recruiting | Phase 3 | Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer | February 15, 2023 | September 1, 2024 |
NCT05454358 | Recruiting | Phase 2/Phase 3 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | August 2, 2022 | July 9, 2030 |
NCT05483023 | Recruiting | Phase 2 | 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy | February 15, 2024 | December 2026 |
NCT05489211 | Recruiting | Phase 2 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | September 6, 2022 | August 19, 2026 |
NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
NCT05500508 | Recruiting | Phase 1/Phase 2 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | November 29, 2022 | September 30, 2024 |
NCT05504161 | Recruiting | Detection of Tumor DNA Through Cervical Smear and Liquid Biopsy in Endometrial Cancer Patients and Evaluation of Prognostic and Predictive Values of Tumor DNA Assay | December 30, 2020 | December 2023 | |
NCT05520099 | Recruiting | Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | June 26, 2023 | January 2027 | |
NCT05527184 | Recruiting | Phase 1 | First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | January 11, 2023 | December 30, 2025 |
NCT05542407 | Recruiting | Phase 1 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | August 16, 2023 | January 15, 2025 |
NCT05559879 | Recruiting | Phase 1/Phase 2 | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma | August 20, 2023 | December 2025 |
NCT05572684 | Recruiting | Phase 1/Phase 2 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | October 6, 2022 | November 2025 |
NCT05579366 | Recruiting | Phase 1/Phase 2 | PRO1184 for Advanced Solid Tumors | December 7, 2022 | April 2026 |
NCT05591131 | Recruiting | N/A | Genetic Testing in African Americans | April 20, 2023 | November 2027 |
NCT05610501 | Recruiting | Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. | May 1, 2021 | April 30, 2024 | |
NCT05611931 | Recruiting | Phase 3 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | April 18, 2023 | January 31, 2028 |
NCT05634499 | Recruiting | Phase 2 | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | June 27, 2023 | December 31, 2025 |
NCT05635123 | Recruiting | A Cohort Study of Uterine Malignancies | September 15, 2023 | December 1, 2030 | |
NCT05640999 | Recruiting | Phase 2 | Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | December 19, 2022 | June 30, 2029 |
NCT05655598 | Recruiting | Phase 1 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | September 12, 2023 | August 2025 |
NCT05677048 | Recruiting | N/A | Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | April 14, 2023 | October 31, 2027 |
NCT05683418 | Recruiting | Phase 1 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | February 15, 2023 | December 2025 |
NCT05691010 | Recruiting | Early Phase 1 | A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | January 10, 2023 | January 10, 2025 |
NCT05697601 | Recruiting | Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools | February 28, 2023 | June 30, 2024 | |
NCT05707312 | Recruiting | Staging Endometrial caNcer Based on molEcular ClAssification | January 1, 2023 | December 31, 2023 | |
NCT05728814 | Recruiting | DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer | March 7, 2023 | September 12, 2024 | |
NCT05737797 | Recruiting | N/A | Non-Invasive Diagnosis of Endometrial Cancer | March 3, 2023 | October 10, 2024 |
NCT05738902 | Recruiting | Adherence and Compliance to ERAS in Gynecological Surgery | May 30, 2023 | March 31, 2025 | |
NCT05743517 | Recruiting | N/A | Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) | September 15, 2023 | August 1, 2029 |
NCT05761951 | Recruiting | Phase 2 | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | August 29, 2023 | January 31, 2029 |
NCT05797831 | Recruiting | Phase 2/Phase 3 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | July 17, 2023 | July 2027 |
NCT05807672 | Recruiting | Magnetic Resonance Fingerprinting in the Imaging of Endometrial Cancer | April 23, 2022 | December 31, 2025 | |
NCT05812677 | Recruiting | Early Phase 1 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer | February 6, 2023 | February 6, 2026 |
NCT05819892 | Recruiting | Phase 1 | Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | July 17, 2023 | March 1, 2028 |
NCT05827614 | Recruiting | Phase 1 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications | March 24, 2023 | September 30, 2027 |
NCT05855941 | Recruiting | Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN) | May 23, 2023 | May 2032 | |
NCT05857631 | Recruiting | N/A | Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study | May 29, 2023 | May 25, 2029 |
NCT05858736 | Recruiting | Phase 1 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors | July 11, 2023 | June 15, 2025 |
NCT05876130 | Recruiting | N/A | Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer | November 1, 2022 | December 31, 2031 |
NCT05887492 | Recruiting | Phase 1/Phase 2 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | June 12, 2023 | June 2025 |
NCT05912972 | Recruiting | Development and Management of Registry in Patients With Gynecologic Cancer in Korea | October 21, 2022 | October 21, 2027 | |
NCT05914974 | Recruiting | Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies | September 11, 2023 | April 2035 | |
NCT05955079 | Recruiting | Circulating Tumor DNA Study in Patients With Endometrial Cancer | January 1, 2021 | January 2026 | |
NCT05955105 | Recruiting | Phase 1/Phase 2 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | July 25, 2023 | July 24, 2026 |
NCT05969405 | Recruiting | Comparison of Prognosis in Endometrial Cancer Treated With Different Surgical Methods: Laparoscopy, Robotic-assisted Laparoscopy and Laparotomy | July 7, 2023 | December 31, 2024 | |
NCT05979610 | Recruiting | Phase 2 | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies | October 9, 2023 | April 1, 2027 |
NCT05990426 | Recruiting | N/A | Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy | October 16, 2023 | August 2026 |
NCT05997017 | Recruiting | Phase 2 | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | December 28, 2023 | October 2026 |
NCT06014190 | Recruiting | Phase 2 | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | December 18, 2023 | December 31, 2027 |
NCT06014580 | Recruiting | Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil | November 27, 2023 | September 30, 2025 | |
NCT06024109 | Recruiting | Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy | March 19, 2024 | January 2026 | |
NCT06028724 | Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) | May 26, 2023 | May 31, 2030 | |
NCT06036836 | Recruiting | Phase 2 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | September 29, 2023 | March 9, 2027 |
NCT06038032 | Recruiting | N/A | ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial | March 25, 2024 | March 2028 |
NCT06083779 | Recruiting | Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics | August 1, 2023 | April 30, 2024 | |
NCT06096688 | Recruiting | Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | May 29, 2019 | December 31, 2026 | |
NCT06132958 | Recruiting | Phase 3 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | December 6, 2023 | January 10, 2028 |
NCT06136884 | Recruiting | Phase 1 | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors | November 2, 2023 | January 27, 2027 |
NCT06163963 | Recruiting | N/A | Sentinel Lymph Node in Early-Stage Endometrium Cancer | July 1, 2023 | May 2026 |
NCT06171789 | Recruiting | Phase 1/Phase 2 | PRO1107 in Patients With Advanced Solid Tumors | January 29, 2024 | February 2027 |
NCT06172478 | Recruiting | Phase 2 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | February 26, 2024 | April 30, 2026 |
NCT06180733 | Recruiting | Phase 2 | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer | December 1, 2023 | January 2028 |
NCT06184867 | Recruiting | Early Phase 1 | Choices About Genetic Testing And Learning Your Risk With Smart Technology | October 26, 2023 | January 31, 2025 |
NCT06206083 | Recruiting | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis | March 1, 2024 | February 1, 2027 | |
NCT06218914 | Recruiting | Phase 1 | A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | February 5, 2024 | January 2, 2040 |
NCT06239194 | Recruiting | Phase 1/Phase 2 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | June 12, 2024 | February 2029 |
NCT06242470 | Recruiting | Phase 1 | A Study of MGC026 in Participants With Advanced Solid Tumors | March 6, 2024 | October 2028 |
NCT06250010 | Recruiting | Immunotolerance in Endometrial Cancer and at the Maternal-fetal Interface: Immunological Profiling of the Tumor Microenvironment in Risk Stratification of Recurrence | December 13, 2022 | December 13, 2025 | |
NCT06257264 | Recruiting | Phase 1 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | February 28, 2024 | December 31, 2026 |
NCT06264921 | Recruiting | Phase 1 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | February 23, 2024 | May 2025 |
NCT06273878 | Recruiting | From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy | January 15, 2023 | January 15, 2025 | |
NCT06276491 | Recruiting | Phase 1 | Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors | April 4, 2024 | December 2028 |
NCT06279832 | Recruiting | N/A | Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer. | November 1, 2023 | October 31, 2025 |
NCT06293898 | Recruiting | Phase 1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | February 9, 2024 | August 24, 2027 |
NCT06294886 | Recruiting | Vaginal Fluid Collection for Detection of Endometrial Cancer | February 19, 2024 | June 1, 2024 | |
NCT06299163 | Recruiting | Phase 1 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | May 1, 2024 | December 31, 2027 |
NCT06307886 | Recruiting | Comparison of Five-year Survival and Disease-free Survival in Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With and Without Uterine Manipulator | September 1, 2023 | September 1, 2028 | |
NCT06321068 | Recruiting | Phase 2/Phase 3 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer | April 9, 2024 | October 2027 |
NCT06339827 | Recruiting | N/A | ASk Questions in GYnecologic Oncology (ASQ-GYO) | April 4, 2024 | May 2027 |
NCT06341855 | Recruiting | N/A | Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer | January 25, 2024 | January 30, 2026 |
NCT06354738 | Recruiting | N/A | Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment | January 16, 2023 | November 1, 2028 |
NCT06395519 | Recruiting | Phase 1 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | May 2024 | December 2026 |
NCT06432478 | Recruiting | N/A | 3D Printed Custom Applicators for HDR BT (DISCO) | November 24, 2023 | September 2028 |
NCT06447064 | Recruiting | Cancer Loyalty Card Study 2 (CLOCS-2) | April 29, 2024 | March 31, 2027 | |
NCT03832361 | Recruiting | Phase 2 | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer | July 15, 2020 | October 2028 |
NCT03860272 | Recruiting | Phase 1 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | April 1, 2019 | December 2026 |
NCT03876860 | Recruiting | N/A | An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis | September 24, 2018 | April 1, 2024 |
NCT03924466 | Recruiting | Phase 2 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | April 1, 2019 | December 2024 |
NCT03931265 | Recruiting | Ketohexokinase Isoforms in Endometrial Cancer. | April 11, 2019 | December 31, 2024 | |
NCT03932409 | Recruiting | Phase 1 | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer | February 19, 2020 | September 2025 |
NCT03955978 | Recruiting | Phase 1 | TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer | October 15, 2019 | July 31, 2026 |
NCT04008563 | Recruiting | N/A | Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium | April 1, 2021 | July 31, 2025 |
NCT04044859 | Recruiting | Phase 1 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | August 20, 2019 | April 30, 2037 |
NCT04080284 | Recruiting | Phase 2 | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma | December 30, 2019 | July 1, 2026 |
NCT04104776 | Recruiting | Phase 1/Phase 2 | A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | September 18, 2019 | March 1, 2026 |
NCT04122235 | Recruiting | N/A | The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study | November 18, 2019 | December 31, 2030 |
NCT04149691 | Recruiting | Phase 1 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | July 19, 2019 | June 2024 |
NCT04196257 | Recruiting | Phase 1 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | August 19, 2022 | October 2024 |
NCT04235179 | Recruiting | Phase 2 | Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer | January 16, 2020 | January 2026 |
NCT04290299 | Recruiting | Endometrial Cancer Conservative Treatment (E.C.Co). A Multicentre Archive | September 15, 2015 | April 8, 2025 | |
NCT04291612 | Recruiting | Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | February 26, 2020 | February 26, 2025 | |
NCT04362046 | Recruiting | N/A | Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia | November 15, 2020 | July 2028 |
NCT04386993 | Recruiting | Phase 1 | De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer | July 7, 2020 | August 31, 2025 |
NCT04403867 | Recruiting | The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study. | January 2, 2020 | January 2027 | |
NCT04453904 | Recruiting | N/A | Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer | May 12, 2020 | April 2027 |
NCT04458402 | Recruiting | N/A | Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer | February 4, 2021 | July 4, 2025 |
NCT05124743 | Suspended | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | September 24, 2021 | May 28, 2028 | |
NCT06253494 | Suspended | Phase 1/Phase 2 | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | May 14, 2024 | December 31, 2028 |
NCT05506800 | Suspended | Guangzhou Women's Health Cohort Study (GWHCS) | March 3, 2016 | August 21, 2026 | |
NCT00161226 | Terminated | A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35 | February 2004 | June 2006 | |
NCT00375804 | Terminated | Racial Disparity in Endometrial Cancer | June 2003 | June 2010 | |
NCT05332483 | Terminated | Phase 1 | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer | July 5, 2022 | October 12, 2023 |
NCT03324958 | Terminated | N/A | VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients. | March 26, 2019 | March 4, 2021 |
NCT04511026 | Terminated | Phase 2 | Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer | January 20, 2021 | June 10, 2021 |
NCT00566644 | Terminated | Phase 3 | Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome | July 2007 | August 2009 |
NCT02558348 | Terminated | Phase 1/Phase 2 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) | November 2015 | May 30, 2017 |
NCT02907073 | Terminated | Phase 1/Phase 2 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | September 2016 | December 2017 |
NCT00471120 | Terminated | N/A | Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer | November 2006 | February 2008 |
NCT02765698 | Terminated | Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer | May 2016 | March 2018 | |
NCT01251354 | Terminated | Phase 2 | Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy | November 2010 | July 2011 |
NCT05107739 | Terminated | Phase 1 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | December 22, 2021 | May 9, 2023 |
NCT02476955 | Terminated | Phase 1 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | June 9, 2015 | May 7, 2019 |
NCT00669422 | Terminated | ChemoFx® PRO - A Post-Market Data Collection Study | October 2006 | October 2012 | |
NCT00003179 | Terminated | Phase 2 | Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer | November 1998 | |
NCT00002976 | Terminated | Phase 3 | Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer | June 1997 | |
NCT02393248 | Terminated | Phase 1/Phase 2 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | February 27, 2015 | December 17, 2021 |
NCT03694834 | Terminated | Early Phase 1 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | March 29, 2019 | October 23, 2023 |
NCT04586335 | Terminated | Phase 1 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | September 28, 2020 | February 15, 2023 |
NCT00394602 | Terminated | Chemoradiation-Induced Nausea and Emesis: Quality of Life | April 7, 2004 | May 8, 2019 | |
NCT02665962 | Terminated | N/A | Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer | July 2015 | July 2018 |
NCT00671606 | Terminated | Phase 2 | Hysteroscopic Lymphatic Mapping for Endometrial Cancer | April 2008 | June 2010 |
NCT03572478 | Terminated | Phase 1/Phase 2 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | August 14, 2018 | October 1, 2020 |
NCT02589366 | Terminated | Phase 1 | Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium | November 2015 | April 2018 |
NCT00900562 | Terminated | Phase 2 | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy | August 2009 | September 2011 |
NCT00883116 | Terminated | Phase 3 | A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer | August 2009 | February 2014 |
NCT03466034 | Terminated | The Role of Hypoxia as a Selective Pressure for TP53 Mutations | February 6, 2018 | July 30, 2019 | |
NCT05877404 | Terminated | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer | August 15, 2023 | February 28, 2024 | |
NCT01401829 | Terminated | Phase 1 | Psychosocial Benefits of Exercise in Endometrial Cancer Survivors | July 2011 | January 2013 |
NCT02566811 | Terminated | N/A | Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC) | April 12, 2017 | August 14, 2019 |
NCT01641497 | Terminated | N/A | Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer | May 2012 | October 2016 |
NCT00016341 | Terminated | Phase 3 | Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer | May 2001 | |
NCT00470067 | Terminated | Phase 2 | Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer | February 2007 | December 2009 |
NCT00003624 | Terminated | Phase 2 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | December 1998 | |
NCT01164150 | Terminated | Phase 2 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 | March 2010 | March 13, 2020 |
NCT04743999 | Terminated | Phase 2 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma | February 27, 2020 | June 27, 2023 |
NCT02042885 | Terminated | Phase 1/Phase 2 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | January 2014 | February 2015 |
NCT04970368 | Terminated | Phase 3 | Comparison of Nodal Staging in Endometrial Cancer | November 5, 2021 | June 13, 2023 |
NCT03099499 | Terminated | Phase 2 | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | June 8, 2017 | September 9, 2020 |
NCT03077698 | Terminated | Phase 2 | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | June 14, 2017 | July 17, 2020 |
NCT04514289 | Unknown status | To Assess and Compare the Performance Two Approach for Sentinel Lymph Node (SNLD) Biopsy for Endometrial Cancer | March 1, 2020 | August 30, 2021 | |
NCT04516083 | Unknown status | Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation | December 21, 2019 | June 30, 2021 | |
NCT04528940 | Unknown status | Tumor Grade Determines PD-1/PDL-1 Expression | August 25, 2020 | September 30, 2021 | |
NCT02433626 | Unknown status | Phase 1 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies | December 2015 | June 2020 |
NCT00916708 | Unknown status | N/A | Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients | September 2008 | December 2020 |
NCT05387460 | Unknown status | Radiomics Based Multimodal Transvaginal Ultrasound Imaging in Endometrial Cancer | October 1, 2021 | July 1, 2023 | |
NCT00003718 | Unknown status | Phase 2 | Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma | September 1998 | |
NCT05427058 | Unknown status | N/A | Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management | August 1, 2022 | April 30, 2023 |
NCT03804463 | Unknown status | N/A | The Multicentic Trial in Fertility-sparing Treatment and Ovarian Preservation Management for Early Endometrial Cancer | January 10, 2019 | December 31, 2021 |
NCT01187706 | Unknown status | A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors | August 2010 | ||
NCT02367950 | Unknown status | N/A | Exercise as an Intervention in Endometrial Cancer Survivors | January 2015 | July 2016 |
NCT04627740 | Unknown status | Phase 1/Phase 2 | Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer | December 1, 2020 | December 31, 2023 |
NCT04651738 | Unknown status | N/A | Cell-free DNA Methylation for Endometrial Cancer | December 18, 2020 | January 1, 2023 |
NCT02188550 | Unknown status | Phase 2 | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | June 2014 | |
NCT04665544 | Unknown status | N/A | Tracers for Endometrial Cancer Sentinel Node Labeling | January 1, 2021 | January 1, 2024 |
NCT02178462 | Unknown status | Biomarkers for Gynecologic Cancer | June 2014 | March 2018 | |
NCT00800644 | Unknown status | Pelvic Fractures and Radiation Therapy for Cervical Cancer | November 5, 2008 | November 30, 2020 | |
NCT04696276 | Unknown status | N/A | Implementing Enhanced Recovery After Surgery (ERAS) Pathways In Major Gynecologic Oncology Operations In Greece | January 6, 2020 | December 30, 2021 |
NCT00905658 | Unknown status | Phase 2 | Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer | June 2008 | |
NCT03744962 | Unknown status | MSI in Circulatory DNA of Endometrial Cancer | November 10, 2018 | December 23, 2020 | |
NCT03827837 | Unknown status | Phase 2 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | January 23, 2019 | December 2022 |
NCT03611517 | Unknown status | N/A | Sexual Rehabilitation Programme After Radiotherapy for Gynaecological Cancer | August 7, 2018 | July 2022 |
NCT03838055 | Unknown status | N/A | Sentinel Node Detection in Endometrial Cancer: A Consolidation Study on Detection Rates of Metastatic Disease | February 2019 | December 2023 |
NCT03595722 | Unknown status | N/A | Exploring HIFU as a Treatment for Rectal and Other Pelvic Cancers | July 11, 2019 | August 28, 2022 |
NCT03567655 | Unknown status | Phase 2 | Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer | July 15, 2018 | November 30, 2022 |
NCT03553589 | Unknown status | Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma | October 1, 2018 | June 1, 2021 | |
NCT00173290 | Unknown status | Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function | July 2004 | December 2006 | |
NCT03538704 | Unknown status | N/A | Effect of Fertility-sparing Therapy of Early Endometrial Cancer | January 1, 2015 | December 31, 2020 |
NCT00373620 | Unknown status | Phase 2 | A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients | January 2006 | |
NCT03489473 | Unknown status | FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment | January 1, 2020 | December 1, 2021 | |
NCT03459976 | Unknown status | HE4 is a Beneficial Biomarker in Endometrial Cancer | December 1, 2017 | April 1, 2019 | |
NCT04010487 | Unknown status | Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis | July 16, 2019 | August 1, 2021 | |
NCT03349463 | Unknown status | Phase 4 | Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. | November 14, 2018 | December 2020 |
NCT01560026 | Unknown status | Retrospective Study to Evaluate the Feasibility of Ovarian Preservation in Patients With Endometrial Carcinoma | August 2000 | December 2012 | |
NCT03322176 | Unknown status | Healthcare Decisions Post-Testing, Risk-reducing and Preventative Strategies Using LYNCH Genetic Testing Reducing, and Preventative Strategies Using LYNCH Genetic Testing | October 17, 2017 | November 1, 2020 | |
NCT04073680 | Unknown status | Phase 1/Phase 2 | A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors | September 1, 2020 | December 30, 2021 |
NCT03207126 | Unknown status | N/A | Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy? | June 13, 2017 | January 1, 2022 |
NCT00601406 | Unknown status | N/A | Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | March 2006 | |
NCT03207061 | Unknown status | N/A | Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer? | June 13, 2017 | January 1, 2022 |
NCT04157491 | Unknown status | Phase 1/Phase 2 | Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer | October 18, 2019 | December 31, 2022 |
NCT00003135 | Unknown status | Phase 2 | Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer | November 1997 | |
NCT03000192 | Unknown status | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | August 2016 | September 2021 | |
NCT02990728 | Unknown status | Phase 2 | Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer | March 2016 | March 2020 |
NCT00982631 | Unknown status | Phase 1 | A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer | June 2009 | August 2012 |
NCT02762214 | Unknown status | Phase 3 | Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY | October 2015 | October 2017 |
NCT04251676 | Unknown status | Radiation Therapy in Uterine Cancer: Dosimetry Analysis, Clinical Implication, and Survival Analysis | January 1, 2010 | December 1, 2021 | |
NCT02684318 | Unknown status | Phase 1/Phase 2 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | July 2015 | October 2019 |
NCT00166985 | Unknown status | The Role of Functional MRI and Doppler Sonography in Assessing Blood Vessel Formation Within the Tumors of Endometrial Cancer Patients | September 2004 | December 2008 | |
NCT01461746 | Unknown status | Phase 2 | Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer | October 2011 | December 2017 |
NCT04295109 | Unknown status | N/A | Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function | March 2, 2020 | July 31, 2020 |
NCT02667431 | Unknown status | Cancer of the Uterus and Treatment of Stress Urinary Incontinence | January 2016 | April 2019 | |
NCT02638402 | Unknown status | Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers | May 2016 | August 2017 | |
NCT02580747 | Unknown status | Phase 1 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | October 2015 | November 2018 |
NCT01447199 | Unknown status | The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) | September 1994 | September 30, 2020 | |
NCT00919919 | Unknown status | Phase 2 | Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen | June 2009 | November 2010 |
NCT04444193 | Unknown status | N/A | Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma | August 31, 2020 | May 31, 2021 |
NCT02560571 | Unknown status | Phase 2 | Pre-operative Studies for Prediction of Lymph Nodes Involvement in Endometrial Cancer Patients | October 2015 | |
NCT05290415 | Unknown status | Host DNA Methylation for Endometrial Cancer Screening | March 13, 2022 | September 13, 2022 | |
NCT05290922 | Unknown status | DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening | March 12, 2022 | March 12, 2023 | |
NCT04489706 | Unknown status | N/A | Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation | June 28, 2020 | November 2022 |
NCT01267851 | Unknown status | Clinical Database and Biobank of Patients With Gynecologic Neoplasms | January 1, 2010 | December 30, 2020 | |
NCT04890912 | Unknown status | N/A | Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II | July 15, 2021 | June 1, 2023 |
NCT01150682 | Unknown status | Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer | July 2010 | ||
NCT00003560 | Unknown status | Phase 2 | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | May 1998 | |
NCT01119573 | Unknown status | Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer | May 2010 | ||
NCT01717794 | Unknown status | N/A | Thunderbeat Technology vs Standard Bipolar Electro-surgery in Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for Endometrial Cancer | October 2012 | |
NCT04958278 | Unknown status | Pelvic Sentinel Node Detection Using Indocyanine Green Learning Curve | July 1, 2021 | October 31, 2022 | |
NCT01710085 | Unknown status | N/A | Value of Diffusion Weighted Magnetic Resonance Imaging in Detection of Recurrent Disease in Surgically Treated Cervical and Endometrial Cancer Patients | August 2012 | February 2014 |
NCT01100359 | Unknown status | Phase 2 | Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer | November 2007 | |
NCT05018195 | Unknown status | N/A | Adipocytokines in Endometrial Cancer | September 1, 2021 | July 29, 2022 |
NCT01087268 | Unknown status | Phase 3 | Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer | January 2009 | |
NCT05056259 | Unknown status | Usefulness of 18F-FDG PET/CT in the Initial Staging and Surveillance of Endometrial Cancer Patients | January 1, 2022 | October 2023 | |
NCT00002465 | Unknown status | Phase 1/Phase 2 | High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma | December 1987 | |
NCT01594879 | Unknown status | Phase 2 | Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer | January 2012 | December 2014 |
NCT01853865 | Unknown status | N/A | Follow-up of Endometrial Cancer Patients | May 2013 | April 2019 |
NCT00758056 | Unknown status | Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom | February 2008 | ||
NCT04787159 | Unknown status | Endometrial Cancer International Database | May 2021 | March 2022 | |
NCT01779128 | Unknown status | Early Phase 1 | PET-CT vs. Integrated MR-PET Scanning of GYN Cancers | March 2013 | |
NCT01761409 | Unknown status | Epidemiological Analysis on Endometrial Cancer in Guangdong Province of China | January 2000 | ||
NCT04866394 | Unknown status | N/A | Stereotactic Pelvic Adjuvant Radiation TherApy in Cancers of the UteruS | July 3, 2019 | April 2024 |
NCT02042495 | Withdrawn | Phase 2 | Endometrial Cancer Biomarker Changes Following Exposure to Metformin | August 2016 | |
NCT03836157 | Withdrawn | Phase 2 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | May 31, 2019 | May 2022 |
NCT00003821 | Withdrawn | Phase 2 | Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer | January 1998 | |
NCT01290406 | Withdrawn | Phase 2 | BEZ235 Trial in Patients With Advanced Endometrial Carcinoma | March 2012 | December 2017 |
NCT00118300 | Withdrawn | Phase 1 | Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer | April 2005 | |
NCT02127151 | Withdrawn | Phase 2 | A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer | October 1, 2014 | May 1, 2017 |
NCT03115593 | Withdrawn | N/A | Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer | July 10, 2018 | March 2, 2020 |
NCT00250016 | Withdrawn | Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) | August 2003 | August 2007 | |
NCT02117817 | Withdrawn | Phase 1 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | February 2015 | February 25, 2015 |
NCT01498237 | Withdrawn | Early Phase 1 | Photoacoustic Endoscopy in Endometrial Cancer | January 2012 | December 2012 |
NCT04611139 | Withdrawn | Phase 1 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | December 31, 2021 | June 30, 2024 |
NCT01097239 | Withdrawn | Phase 1/Phase 2 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | November 2009 | September 2018 |
NCT01550380 | Withdrawn | Phase 2 | BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers | May 2014 | July 2014 |
- Exact Synonym (Disease Ontology)
- endometrial Ca
- Exact Synonym (Disease Ontology)
- endometrial neoplasm
- Exact Synonym (Disease Ontology)
- malignant endometrial neoplasm
- Exact Synonym (Disease Ontology)
- malignant neoplasm of endometrium
- Exact Synonym (Disease Ontology)
- neoplasm of endometrium
- Exact Synonym (Disease Ontology)
- primary malignant neoplasm of endometrium
- Exact Synonym (Disease Ontology)
- tumor of Endometrium
- Disase is a (Disease Ontology)
- DOID:363
- Cross Reference ID (Disease Ontology)
- EFO:0004230
- Cross Reference ID (Disease Ontology)
- GARD:11981
- Cross Reference ID (Disease Ontology)
- ICD10CM:C54.1
- Cross Reference ID (Disease Ontology)
- KEGG:05213
- Cross Reference ID (Disease Ontology)
- MESH:D016889
- Cross Reference ID (Disease Ontology)
- MIM:608089
- Cross Reference ID (Disease Ontology)
- NCI:C27815
- Cross Reference ID (Disease Ontology)
- NCI:C3012
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:123844007
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:188192002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0007103
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0014170